Leap Therapeutics reports Q2 EPS (91c), consensus (90c)

Cash and cash equivalents totaled $91.4M at June 30. Research and development incentive receivables totaled $2.6M at June 30. “The company made important progress on our DKN-01 program during the second quarter. Based on Part A of the DeFianCe study exceeding our threshold of a 20% ORR, all of which are now confirmed responses, we initiated Part B, our second randomized controlled trial,” said Douglas Onsi, CEO. “We also presented new long-term follow-up data from Part A of the DisTinGuish study at ASCO, demonstrating 19.5 months median overall survival which exceeds current benchmarks. Additionally, enrollment continues to be strong in the 160 patient randomized controlled Part C of the DisTinGuish study, and we expect to complete enrollment in Q4 of this year.”